{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-22-000191","form_type":"8-K","ticker":"CHE","cik":"0000019584","company_name":"CHEMED CORP","filed_at":"2022-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.041805+00:00","generated_at":"2026-06-26T04:46:44.496657+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Chemed Q1 2022: EPS up 7.9% on adjusted basis; VITAS revenue down 5.3%, Roto-Rooter up 9.4%","bullets":["Consolidated revenue $531M (+0.6% YoY); GAAP diluted EPS $4.22 (+5.2%); adjusted diluted EPS $4.79 (+7.9%).","VITAS net patient revenue $299M (-5.3%), ADC 17,313 (-4.1%), admissions 16,530 (-8.9%).","Roto-Rooter revenue $231M (+9.4%); net income excl. discrete items $46.4M (+18.0%); adjusted EBITDA margin 28.5% (+160 bps).","Chemed repurchased 57,500 shares for $27.4M at avg. cost $475.71; remaining auth. ~$175M.","Management to provide updated 2022 earnings guidance in June 2022 earnings release."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-22-000191","json":"https://secwatch.observer/filing/0001562762-22-000191.json","markdown":"https://secwatch.observer/filing/0001562762-22-000191.md","text":"https://secwatch.observer/filing/0001562762-22-000191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/19584/000156276222000191/0001562762-22-000191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/19584/000156276222000191/che-20220426x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:46:44.496657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}